Viewing nowCombinationJadiflozin M Tablet 12.5/850 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Youngpoong Pharmaceutical Co., Ltd.

MFDS item code 202302695 · Approved 2023.09.11 · Insurance code 661905780
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in adults with type 2 diabetes by combining Empagliflozin and Metformin, along with dietary and exercise therapy. It can be administered to adult type 2 diabetes patients with cardiovascular disease when blood sugar is insufficiently controlled. The safety regarding the occurrence of cardiovascular events should refer to clinical trial data for professionals. Therefore, this medication effectively aids in managing blood sugar levels of diabetic patients and contributes to improving their health status.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and their current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin to this medicine should take the same doses of empagliflozin and metformin as they were previously taking. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose in such cases. No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other symptoms that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to a CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.
This medication is used for the treatment of diabetes and helps in controlling blood sugar levels. When taking this medication, caution is necessary as a rare but serious side effect, lactic acidosis, may occur. Lactic acidosis is a condition arising from a buildup of lactic acid in the body, presenting symptoms like vomiting, abdominal pain, difficulty breathing, and weakness. Additionally, there is a risk of hypoglycemia when taken alongside other diabetes medications, thus it is essential to closely monitor blood sugar levels. Patients with impaired kidney function or those with acute infections, dehydration, or heart diseases should not take this medication, and they must stop its administration immediately if such conditions arise. Intake of this medication should be temporarily suspended before and after examinations using iodinated contrast agents, and it should be resumed only after kidney function has returned to normal. Women who are pregnant or may become pregnant and nursing mothers are advised not to take this medication. During treatment, urinary tract infections or genital infections may occur; hence, consultation with healthcare providers should be sought if any infection symptoms appear. This medication may lead to fluid loss; therefore, vigilance is especially needed in cases of dehydration or among the elderly, as regular kidney function monitoring is necessary. Furthermore, vitamin B12 deficiency may occur, so regular blood tests are recommended. Alcohol consumption should be avoided while taking this medication, and attention is needed during sudden reductions in food intake or vigorous exercise. Patients scheduled for surgery should discontinue this medication 48 hours prior to the procedure and resume only after confirming normal kidney function post-surgery. Hypoglycemic symptoms may arise during treatment, so immediate blood sugar checks and necessary measures should be taken if symptoms like dizziness, cold sweat, and severe fatigue occur. Finally, this medication is not recommended for children, and elderly or frail patients should exercise extra caution when using it.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature to maintain its efficacy and safety over a long period.
A white, oval, biphasic film-coated tablet with a pinkish hue
30 tablets/bottle, 60 tablets/bottle, 10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Youngpoong Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.